Key points {#tca13179-sec-0005}
==========

Significant findings of the study {#tca13179-sec-0006}
---------------------------------

The overall frequency of BRAF^V600E^ mutations in our study was lower than in some other reports. All four of our pulmonary Langerhans cell histiocytosis (PLCH) cases had negative BRAF^V600E^ mutation. BRAF^V600E^ mutations might not be correlated with age, gender, LCH classification type or prognosis for Chinese cases.

What this study adds {#tca13179-sec-0007}
--------------------

The BRAF^V600E^ mutation rate in LCH varies.

Introduction {#tca13179-sec-0008}
============

As V‐rf murine sarcoma viral oncogene homolog B1 (BRAF)^V600E^ mutations are present in approximately half the samples from patients with Langerhans cell histiocytosis (LCH), and treatment with BRAF inhibitors has been reported to be effective for some patients with LCH, the identification of BRAF^V600E^ mutations is recommended for all patients with LCH with difficult diagnosis and failure of first‐line treatment (grade C2).[1](#tca13179-bib-0001){ref-type="ref"} The reported frequencies of BRAF^V600E^ mutations in patients with LCH vary among different ethnicities or countries.[2](#tca13179-bib-0002){ref-type="ref"} No BRAF^V600E^ mutations were reported in adults with LCH in the study by Tong *et al*.,[3](#tca13179-bib-0003){ref-type="ref"} but in the studies by Wei *et al*. and Zeng *et al*.,[4](#tca13179-bib-0004){ref-type="ref"}, [5](#tca13179-bib-0005){ref-type="ref"} the frequencies of BRAF^V600E^ mutations were 17.3% and 15.6% for Chinese adult patients with LCH and 46.4% and 32% for all recruited patients with LCH, respectively. Here, we retrospectively analyzed BRAF^V600E^ mutations and the clinical features of patients with LCH with a positive pathological diagnosis at our hospital over the last five years.

Methods {#tca13179-sec-0009}
=======

Patients {#tca13179-sec-0010}
--------

A computer‐assisted search for patients hospitalized at Peking Union Medical College Hospital from January 2013 to December 2017 identified 167 patients diagnosed with LCH according to the 2016 World Health Organization criteria.[1](#tca13179-bib-0001){ref-type="ref"} Most patients were diagnosed by our pathologist in consultation with biopsy/surgical samples from other hospitals. Finally, 67 patients with complete medical records, radiologic images and pathological specimens were retrospectively recruited into this study. All patients were followed‐up every one to six months, depending on disease activity and treatment. The mean follow‐up period was 36.8 months, ranging from seven to 59 months.

All patients underwent chest CT scans, cerebral magnetic resonance imaging, bone scintigraphy scans, whole body bone plain films, and bone marrow biopsies, and 26 patients underwent ^18F^fluorodeoxyglucose (FDG) positron emission tomography (PET) scans. The involved sites were defined according to the typical imaging scans and/or the pathological manifestations.

The following information was analyzed: age, sex, clinical manifestations, serological results, radiologic findings, pathological manifestations, treatments and outcomes. Hematoxylin‐eosin (HE) staining and immunohistochemical (IHC) staining analysis of CD68, CD1a, CD207, and S100 were performed for all enrolled patients. All glass slides were reviewed and scored by two pathologists (R.E.F. and J.L.), who were blinded to the molecular results. The two pathologists independently came to a consensus diagnosis based on the WHO recommendations for all enrolled patients.[6](#tca13179-bib-0006){ref-type="ref"}

All patients and/or their relatives provided written informed consent. This study was approved by the ethics committee of Peking Union Medical College Hospital (JS‐1127, ZS‐1058), in accordance with the Declaration of Helsinki.

DNA extraction {#tca13179-sec-0011}
--------------

Tumor DNA was extracted from formalin‐fixed, paraffin‐embedded tissues from our pathological sample bank. Following HE and immunohistochemical staining, the samples with the highest CD1a‐positive histiocyte density were selected for further BRAF mutation analysis.

DNA was extracted from the collected tissue samples using the QIAGEN QIAamp DNA FFPE Tissue Kit (154051332, QIAGEN China (Shanghai) Co. Ltd., Shanghai, China), following the manufacturer\'s protocol.

Detection of BRAF^V600E^ mutations by PCR analysis {#tca13179-sec-0012}
--------------------------------------------------

The BRAF^V600E^ mutations were detected with the human BRAF^V600E^ ARMS‐PCR kit (P216010801Y, Amoy Diagnostics Co. Ltd., Xiamen, China), which has been approved by the China Food and Drug Administration. The extracted DNA quality was evaluated by amplification of a housekeeping gene following the instructions in the HEX channel. PCR was performed on the PCR System 7500 (ABI) system for 47 cycles according to the instructions supplied with the BRAF^V600E^ ARMS‐PCR kit. Both negative and positive controls were included in each set of amplifications. The sequencing results were analyzed and interpreted according to the manufacturer\'s protocol.

Statistical analysis {#tca13179-sec-0013}
--------------------

Data were analyzed using the Statistical Analysis System (SAS) version 9.0 software package. Quantitative variables are presented as the mean ± standard deviation (SD), and categorical data are presented as the frequency and percentage in the text and figures.

Results {#tca13179-sec-0014}
=======

General clinical characteristics {#tca13179-sec-0015}
--------------------------------

The general clinical characteristics of the 67 enrolled patients are summarized in Table [1](#tca13179-tbl-0001){ref-type="table"}. The study group consisted of 46 male (68.7%) and 21 female (31.3%) patients, with a mean age of 29.1 years (range, 2--76 years). Most were adults, with 22 (32.8%) younger than 18 years and two (3.0%) older than 60 years. According to the 2016 WHO classification criteria for LCH, 18 patients (28.7%) had Single system‐LCH (SS‐LCH) type, seven (10.4%) had multisystem‐LCH (MS‐LCH) risk organ (RO)^+^ type and 42 (62.9%) had MS‐LCH‐RO^−^ type.

###### 

General clinical characteristics for all enrolled cases

  Case   Gender    Age (years)  Involved organ/tissue                                  Subtypes   Biopsy site                            BRAF^V600E^ status   Treatment                             Outcomes
  ------ -------- ------------- ------------------------------------------------------ ---------- -------------------------------------- -------------------- ------------------------------------- --------------
  1      M             43       Lung                                                   SS         VATS lung biopsy                       WT                   Quit smoking                          Cured
  2      M             15       Pituitary                                              SS         surgical pituitary biopsy              WT                   Radiotherapy                          Improved
  3      M             17       Maxillary sinus                                        SS         surgical maxillary sinus mass biopsy   WT                   Surgery                               Cured
  4      M             22       Lung, pituitary, mandible, vertebrae                   MS‐RO^−^   VATS lung biopsy, mandible biopsy      WT                   Chemotherapy                          Relapse
  5      F             36       Pituitary, mandible                                    MS‐RO^−^   Surgical pituitary biopsy              WT                   Radiotherapy                          Improved
  6      F              2       Skull, pituitary                                       MS‐RO^−^   Surgical skull biopsy                  V600E                Chemotherapy                          Improved
  7      F             12       Lung, liver, pituitary                                 MS‐RO^+^   Surgical hepatic biopsy                WT                   Chemotherapy                          Improved
  8      M             51       Lung, pituitary                                        MS‐RO^−^   VATS lung biopsy                       WT                   Chemotherapy                          Improved
  9      M             73       Lymph nodes, skin                                      MS‐RO^−^   Surgical lymph node biopsy             WT                   Chemotherapy                          Improved
  10     M             12       Left humerus                                           SS         Surgical bone biopsy                   WT                   Surgery, radiotherapy                 Improved
  11     M             55       Lung, oral mucosa, lymph node                          MS‐RO^−^   Surgical mucosa biopsy                 V600E                Chemotherapy                          Improved
  12     M             37       Femur                                                  SS         Surgical bone biopsy                   WT                   Surgery                               Cured
  13     M             26       Lung, vertebrae, liver, pituitary                      MS‐RO^+^   Surgical bone and liver biopsy         WT                   Chemotherapy, liver transplantation   Relapse
  14     M             15       Lung, pituitary, thyroid                               MS‐RO^−^   Surgical thyroid resection             WT                   Surgery, chemotherapy                 Improved
  15     M             39       Pituitary                                              SS         Surgical pituitary biopsy              WT                   Radiotherapy, surgery                 Improved
  16     M             13       Pituitary                                              SS         Surgical pituitary biopsy              WT                   Surgery                               Improved
  17     M             37       Lung, thyroid                                          MS‐RO^−^   Thyroid fine needle biopsy             WT                   Chemotherapy                          Improved
  18     M              5       Vertebrae                                              SS         Surgical bone biopsy                   V600E                Surgery                               Cured
  19     F              6       Vertebrae                                              SS         Surgical bone biopsy                   V600E                Surgery                               Cured
  20     F              9       Pituitary                                              SS         Surgical pituitary biopsy              WT                   Surgery, radiotherapy                 Improved
  21     F             14       Pituitary, vertebrae, skin                             MS‐RO^−^   Surgical bone biopsy                   WT                   Surgery, chemotherapy                 Improved
  22     F             25       Pituitary                                              SS         Surgical pituitary biopsy              WT                   Surgery, radiotherapy                 Improved
  23     F             43       Skull                                                  SS         Surgical bone biopsy                   WT                   Surgery, chemotherapy                 Improved
  24     M             76       Multiple lymph nodes                                   MS‐RO^−^   Surgical lymph node biopsy             WT                   Chemotherapy                          Exacerbation
  25     M             42       Lung, mandible                                         MS‐RO^−^   Surgical mandible biopsy               V600E                Chemotherapy                          Improved
  26     M             17       Skull, femur, pituitary                                MS‐RO^−^   Surgical bone biopsy                   V600E                Chemotherapy                          Improved
  27     M             12       Skull, femur, vertebrae, pituitary                     MS‐RO^−^   Surgical bone biopsy                   WT                   Chemotherapy                          Improved
  28     M             43       Pituitary, vertebrae, tibia                            MS‐RO^−^   Surgical bone biopsy                   V600E                Chemotherapy                          Improved
  29     M             12       Vertebrae                                              SS         Surgical bone biopsy                   WT                   Surgery, radiotherapy                 Improved
  30     F             49       Lung, pituitary, liver, lymph node                     MS‐RO^+^   VATS lung biopsy, skin biopsy          WT                   Chemotherapy                          Improved
  31     M             28       Lung, pituitary, skin                                  MS‐RO^−^   VATS lung biopsy                       WT                   Chemotherapy                          Improved
  32     F             17       Lung, pituitary, skin, lymph node                      MS‐RO^−^   Skin biopsy                            WT                   Chemotherapy                          Relapse
  33     M             21       Lung, thyroid, pituitary, liver, lymph node            MS‐RO^+^   Thyroid fine needle biopsy             WT                   Chemotherapy, thyroid radiotherapy    Improved
  34     M             15       Pituitary, liver, lymph node                           MS‐RO^+^   Liver fine needle biopsy               WT                   Chemotherapy                          Improved
  35     M              8       Lung, thyroid, pituitary, lymph node                   MS‐RO^−^   Thyroid fine needle biopsy             WT                   Chemotherapy                          Improved
  36     M             24       Lung, skull, pituitary, skin, stomach                  MS‐RO^−^   Stomach and skin biopsy                V600E                Chemotherapy                          Exacerbation
  37     F             14       Skull, pituitary                                       MS‐RO^−^   Surgical bone biopsy                   WT                   Surgery, chemotherapy                 Improved
  38     M             20       Pituitary, skin                                        MS‐RO^−^   Skin biopsy                            WT                   Surgery                               Improved
  39     M             31       Lung, skin, muscle, lymph node                         MS‐RO^−^   Surgical muscle biopsy                 WT                   Chemotherapy                          Improved
  40     M              7       Skull, radius, vertebrae, pituitary                    MS‐RO^−^   Surgical bone biopsy                   WT                   Surgery, chemotherapy                 Improved
  41     M             39       Skull, vertebrae, lung                                 MS‐RO^−^   Surgical bone biopsy                   WT                   Chemotherapy                          Improved
  42     F             32       Skin, lymph node, liver                                MS‐RO^+^   Lymph node biopsy                      WT                   Chemotherapy                          Improved
  43     M             14       Lung, pituitary                                        MS‐RO^−^   Surgical pituitary biopsy              WT                   Chemotherapy                          Improved
  44     F             23       Skull                                                  MS‐RO^−^   Surgical bone biopsy                   V600E                Surgery                               Cured
  45     F             52       Rib                                                    MS‐RO^−^   Surgical bone biopsy                   V600E                Surgery                               Cured
  46     M             38       Lung, skin, pituitary, thyroid                         MS‐RO^−^   Thyroid fine needle biopsy             WT                   Chemotherapy                          Relapse
  47     M             28       Lung, alveolar bone                                    MS‐RO^−^   VATS lung biopsy, bone biopsy          WT                   ---                                   Died
  48     F             12       Lung, pituitary                                        MS‐RO^−^   Surgical pituitary biopsy              WT                   Chemotherapy                          Improved
  49     M             42       Lung                                                   SS         VATS lung biopsy                       WT                   Quit smoking                          Cured
  50     F             32       Lung, pituitary                                        MS‐RO^−^   VATS lung biopsy                       WT                   ---                                   Stable
  51     F             25       Skull, vertebrae, skin                                 MS‐RO^−^   Skin biopsy                            WT                   Chemotherapy                          Improved
  52     M             16       Lung, pituitary                                        MS‐RO^−^   Transbronchial lung biopsy             V600E                Chemotherapy                          Improved
  53     M             23       Lung, skull, pituitary, thyroid                        MS‐RO^−^   Thyroid fine needle biopsy             WT                   Chemotherapy                          Improved
  54     M             54       Vertebrae, pituitary                                   MS‐RO^−^   Surgical bone biopsy                   WT                   Chemotherapy                          Improved
  55     F             47       Lung, femur, pituitary, thyroid                        MS‐RO^−^   Surgical thyroid resection             V600E                Surgery, chemotherapy                 Improved
  56     M             31       Lung, skull, pituitary, skin                           MS‐RO^−^   Skin biopsy                            V600E                Chemotherapy                          Improved
  57     F             31       Femur, skull, vertebrae, rib, oral mucosa, pituitary   MS‐RO^−^   Oral mucosa biopsy                     V600E                Chemotherapy                          Improved
  58     M             25       Pituitary                                              SS         Surgical pituitary biopsy              WT                   Surgery, radiotherapy                 Improved
  59     F             24       Lung, thyroid, pituitary                               MS‐RO^−^   Thyroid fine needle biopsy             WT                   Chemotherapy                          Improved
  60     M             57       Lung, liver, lymph nodes                               MS‐RO^+^   Surgical lymph node biopsy             WT                   Chemotherapy                          Improved
  61     M             24       Skull, vertebrae, pituitary                            MS‐RO^−^   Surgical bone biopsy                   WT                   Chemotherapy                          Improved
  62     M             27       Lung, pituitary                                        MS‐RO^−^   VATS lung biopsy                       WT                   Chemotherapy                          Improved
  63     M             47       Lung                                                   SS         VATS lung biopsy                       WT                   Quit smoking                          Cured
  64     M             47       Skull                                                  SS         Surgical bone biopsy                   V600E                Chemotherapy                          Improved
  65     M             29       Skull, pituitary                                       MS‐RO^−^   Surgical bone biopsy                   WT                   Chemotherapy                          Improved
  66     M             35       Lung                                                   SS         VATS lung biopsy                       WT                   Quit smoking                          Improved
  67     F             48       Lung, pituitary                                        MS‐RO^−^   Surgical pituitary biopsy              WT                   Chemotherapy                          Improved

F, female; M, male; MS, multisystem; RO, risk organ; SS, single system; VATS, video‐assisted thoracic surgery; WT, wild type.

The BRAF^V600E^ molecular analysis was successful for all 67 enrolled patients. The overall frequency of BRAF^V600E^ mutations was 22.4% (15 of 67 patients) according to the PCR analysis. The main involved sites included the pituitary gland (42/62.7%), lung (33/49.3%), skull (16/23.9%), vertebrae (14/20.9%), lymph nodes (11/16.4%), skin (11/16.4%), thyroid gland (8/11.9%), limb bone (8/11.9%), and liver (7/10.4%). Most patients (50/74.6%) improved after surgery, chemotherapy and/or radiotherapy. Nine patients (13.4%) were cured after surgical resection (6/9%) or after quitting smoking (3/4.5%). Four patients (4/6%) relapsed, and two patients (2/3%) experienced exacerbation of the disease, although they underwent chemotherapy. One patient (1/1.5%) was stable without treatment, and one (1/1.5%) died of respiratory failure.

Clinical characteristics of patients with different BRAF^V600E^ statuses {#tca13179-sec-0016}
------------------------------------------------------------------------

The clinical characteristics of patients with different BRAF^V600E^ mutation statuses are shown in Table [2](#tca13179-tbl-0002){ref-type="table"}. These mutations were not closely correlated with age (nonadults vs. adults = 5/22.7% vs. 10/22.2%, *P* = 1.00), gender (female vs. male = 9/19.6% vs. 6/28.6%, *P* = 0.61), LCH classification type (SS: MS‐RO^+^: MS‐RO^−^ = 3/16.7%: 12:28.6%: 0, *P* = 0.19), or prognosis (cured: improved/stable: exacerbated: died = 4/44.4%: 19.2%: 20%: 0, *P* = 0.37). As the pituitary gland, lung and thyroid were the most common associated organs in our cohort, the associations between the involvement of these organs and BRAF^V600E^ mutation status were analyzed. However, there were no differences in the prevalence of the BRAF^V600E^ mutation between patients with involvement of the pituitary gland, lung and thyroid and patients with other involved sites. In addition, all the LCH patients with liver involvement were negative for BRAF^V600E^ mutations. There were no correlations between BRAF^V600E^ mutations status and the prognosis.

###### 

The clinical characteristics of patients with different BRAF^V600E^ mutations

                              Characteristics         Mutation type (*n*)    Wild type (n)   *P*‐value  
  --------------------------- ----------------------- --------------------- --------------- ----------- ------
  Children                    Gender                  Male                         3            11       1.00
  Female                      2                       6                                                 
  LCH subtype                 SS                      2                            6           1.00     
  MS‐RO^+^ & MS‐RO^−^         3                       9                                                 
  Lung involvement            Yes                     1                            6           1.00     
  No                          4                       11                                                
  Pituitary involvement       Yes                     3                           15           0.21     
  No                          2                       2                                                 
  Thyroid involvement         Yes                     0                            2           1.00     
  No                          5                       15                                                
  Prognosis                   Cured/improved/stable   5                           16           1.00     
  Exacerbation/relapse/died   0                       1                                                 
  Adults                      Gender                  Male                         6            26       0.63
  Female                      4                       9                                                 
  LCH subtype                 SS                      1                            9           0.53     
  MS‐RO^+^ & MS‐RO^−^         9                       26                                                
  Lung involvement            Yes                     5                           21           0.84     
  No                          5                       14                                                
  Pituitary involvement       Yes                     5                           19           1.00     
  No                          5                       16                                                
  Thyroid involvement         Yes                     1                            5           1.00     
  No                          9                       30                                                
  Prognosis                   Cured/improved/stable   9                           30           1.00     
  Exacerbation/relapse/died   1                       5                                                 

LCH, Langerhans cell histiocytosis; MS, multisystem; RO, risk organ; SS, single system.

Patients with LCH with pulmonary involvement {#tca13179-sec-0017}
--------------------------------------------

Pulmonary involvement is frequently present in systemic forms of LCH. In addition, pulmonary LCH (PLCH) is restricted to the lungs.[7](#tca13179-bib-0007){ref-type="ref"} Among the 67 patients with LCH in this study, there were 33 patients (49.2%) who had lung involvement. In addition, 12 patients (36.3%) underwent lung biopsies. After multiple screening tests, only four patients (12.1%) were diagnosed with PLCH, and none were positive for BRAF^V600E^ mutations. The clinical characteristics of patients with or without lung involvement LCH are shown in Table [3](#tca13179-tbl-0003){ref-type="table"}. Lung involvement was more common in patients with the MS‐LCH subtype (*P* = 0.006), and patients with thyroid gland involvement (100% vs. 36.2*%*, *P* = 0.0073). After either surgical or fine needle biopsy, eight patients were diagnosed with LCH with thyroid involvement. The imaging studies of these eight patients showed classic lung shadows indicating diffuse cysts with bizarre shapes.

###### 

The clinical characteristics of patients with or without lung involvement LCH

                                  Characteristics     Lung involvement (*n*)    Without lung involvement (*n*)   *P*‐value  
  --------------------------- ----------------------- ------------------------ -------------------------------- ----------- -------
  Children                            Gender          Male                                    4                     10      1.000
  Female                                 3            5                                                                     
  LCH subtype                           SS            0                                       8                    0.022    
  MS‐RO^+^ & MS‐RO^−^                    7            7                                                                     
  BRAF^V600E^status                     WT            6                                       11                   1.000    
  MT                                     1            4                                                                     
  Pituitary involvement                 Yes           7                                       11                   0.263    
  No                                     0            4                                                                     
  Thyroid involvement                   Yes           2                                       0                    0.091    
  No                                     5            15                                                                    
  Prognosis                    Cured/improved/stable  6                                       15                   0.318    
  Exacerbation/relapse/died              1            0                                                                     
  Adults                              Gender          Male                                    21                    11      0.094
  Female                                 5            8                                                                     
  LCH subtype                           SS            4                                       6                    0.354    
  MS‐RO^+^ & MS‐RO^−^                   22            13                                                                    
  BRAF^V600E^status                     WT            21                                      14                   0.840    
  MT                                     5            5                                                                     
  Pituitary involvement                 Yes           14                                      10                   0.936    
  No                                    12            9                                                                     
  Thyroid involvement                   Yes           6                                       0                    0.071    
  No                                    20            19                                                                    
  Prognosis                    Cured/improved/stable  21                                      18                   0.359    
  Exacerbation/relapse/died              5            1                                                                     

LCH, Langerhans cell histiocytosis; MS, multisystem; RO, risk organ; SS, single system; WT, wild type.

In our cohort, most of the patients with LCH with lung involvement were patients with systemic LCH. All four patients with PLCH were smokers. Three were cured after quitting smoking and avoiding secondhand smoke for four to six months, without medications. The fourth patient with PLCH was diagnosed three months prior to this manuscript being written, and his lung infiltrations improved after quitting smoking, without taking medication. Although all patients with PLCH had good prognoses, there was no difference in prognosis between patients with LCH with and without lung involvement.

Discussion {#tca13179-sec-0018}
==========

The BRAF gene is located on chromosome 7q34, and is a member of the RAF kinase family. Although mutations of BRAF have been identified in a large number of solid tumors, it was first reported by Badalian‐Very *et al*. in 2010 that BRAF^V600E^ expression was identified in 57% of samples from patients with LCH.[8](#tca13179-bib-0008){ref-type="ref"} Following this study, there were several studies that focused on the mitogen‐activated protein kinase (MAPK) pathway signal transmission, including BRAF^V600E^,[2](#tca13179-bib-0002){ref-type="ref"}, [8](#tca13179-bib-0008){ref-type="ref"}, [9](#tca13179-bib-0009){ref-type="ref"}, [10](#tca13179-bib-0010){ref-type="ref"}, [11](#tca13179-bib-0011){ref-type="ref"}, [12](#tca13179-bib-0012){ref-type="ref"}, [13](#tca13179-bib-0013){ref-type="ref"} mitogen‐activated protein kinase 1 (MAP2K1) and NRAS.[14](#tca13179-bib-0014){ref-type="ref"}, [15](#tca13179-bib-0015){ref-type="ref"}, [16](#tca13179-bib-0016){ref-type="ref"}, [17](#tca13179-bib-0017){ref-type="ref"} It was reported that the activating BRAF^V600E^ mutation rate ranged from 35% to 60% in different studies using PCR or immunohistochemistry (IHC) staining[2](#tca13179-bib-0002){ref-type="ref"}, [8](#tca13179-bib-0008){ref-type="ref"}, [9](#tca13179-bib-0009){ref-type="ref"}, [10](#tca13179-bib-0010){ref-type="ref"}, [11](#tca13179-bib-0011){ref-type="ref"}, [12](#tca13179-bib-0012){ref-type="ref"} in patients with LCH. According to the review by Selway *et al*. the BRAF^V600E^ mutation rate was 51.13% in 397 patients with LCH.[18](#tca13179-bib-0018){ref-type="ref"} The mutation rate varies across different studies and different races. The BRAF^V600E^ mutation rates reported in Chinese patients with LCH were 0 in the study by Tong *et al*. ^3^ 56% in the study by Wei *et al*. and 22.5% in our study.[4](#tca13179-bib-0004){ref-type="ref"}

The patient age distribution, involved sites, stage, and different detection tests might influence the BRAF^V600E^ subtype.[3](#tca13179-bib-0003){ref-type="ref"}, [8](#tca13179-bib-0008){ref-type="ref"}, [19](#tca13179-bib-0019){ref-type="ref"} Badalian‐Very *et al*.[8](#tca13179-bib-0008){ref-type="ref"} and Héritier *et al*.[13](#tca13179-bib-0013){ref-type="ref"} reported that younger LCH patients tended to be positive for BRAF^V600E^ mutations, and most patients with BRAF^V600E^ mutations in the study by Wei *et al*. had bone involvement or the MS‐LCH subtype[4](#tca13179-bib-0004){ref-type="ref"}; in the study by Tong *et al*. ^3,4,8^ skin and lung were the most commonly involved sites, and 77.8% of the patients had the LCH‐SS subtype. However, according to the meta‐analysis of existing LCH BRAF^V600E^ studies by Selway *et al*. there was no difference in the presence of BRAF^V600E^ mutations between adults and children, between those with the SS‐LCH and MS‐LCH subtypes, and those with different involved sites.[18](#tca13179-bib-0018){ref-type="ref"} In our cohort, BRAF^V600E^ mutations were not correlated with age, gender, LCH classification type, or prognosis. According to the meta‐analysis by Selway *et al*. and the study by Heritier *et al*. on the BRAF^V600E^ mutation in patients with LCH,[13](#tca13179-bib-0013){ref-type="ref"}, [18](#tca13179-bib-0018){ref-type="ref"} the rate of the BRAF^V600E^ mutation was increased in patients who experienced involvement of higher risk organs, such the liver and spleen. In the study by Selway *et al*.,[18](#tca13179-bib-0018){ref-type="ref"} although 75% of the biopsied liver samples were positive for BRAF^V600E^ mutations, none of our patients with LCH with liver involvement had BRAF^V600E^ mutations.

The lung is a commonly involved site in patients with LCH, and PLCH has been commonly reported in previous studies. However, only four patients (6%) in our cohort were diagnosed with solitary PLCH. Most of the previous studies did not show the completed screening tests for the enrolled patients with LCH.[2](#tca13179-bib-0002){ref-type="ref"}, [4](#tca13179-bib-0004){ref-type="ref"}, [8](#tca13179-bib-0008){ref-type="ref"}, [10](#tca13179-bib-0010){ref-type="ref"}, [11](#tca13179-bib-0011){ref-type="ref"}, [12](#tca13179-bib-0012){ref-type="ref"}, [13](#tca13179-bib-0013){ref-type="ref"}, [14](#tca13179-bib-0014){ref-type="ref"}, [15](#tca13179-bib-0015){ref-type="ref"}, [16](#tca13179-bib-0016){ref-type="ref"} In our study, all 67 patients underwent strict screening tests including chest CTs, cranial MRIs, bone scans and bone marrow biopsies, with the exception of detailed serum tests. In addition, 26 patients underwent ^18F^FDG‐PET‐CT scans, which is a useful and sensitive tool for the identification of active lesions, the stratification of disease stages, and the monitoring of a therapeutic response in patients with LCH.[20](#tca13179-bib-0020){ref-type="ref"} Most of our patients with lung involvement were diagnosed with the MS‐LCH subtype after these screening tests, and only four patients were diagnosed with solitary PLCH.

Solitary PLCH is a smoking‐related non‐neoplastic disease, and the study by Yousem *et al*. failed to show clonality in patients with PLCH.[21](#tca13179-bib-0021){ref-type="ref"} However, some studies reported BRAF^V600E^ mutation rates ranging from 28% to 89% in patients with PLCH.[22](#tca13179-bib-0022){ref-type="ref"} In our study, all four PLCH patients smoked, and all were negative for BRAF^V600E^ mutations. Three of them were cured, and the fourth patient experienced improvement after quitting smoking and avoiding secondhand smoke, without medications. The natural history of PLCH varied widely. Some patients with PLCH may remit or stabilize after quitting smoking. However, others may develop pulmonary fibrosis, pulmonary hypertension, and respiratory failure, even after chemotherapy. There has been no further analysis of the BRAF^V600E^ mutation status for those self‐cured PLCH patients in most studies.

There were several limitations in our study. First, all enrolled patients had a definitive diagnosis of LCH and had complete clinical records, radiological images and pathological specimen, which could cause a selection bias. The BRAF^V600E^ mutations in our study were detected by PCR analysis, and the DNA was extracted from formalin‐fixed paraffin‐embedded tissues, which could minimize the sensitivity. Second, not all enrolled patients underwent lung biopsies. There were 33 patients (49.2%) who had lung involvement, but only 12 patients (36.3%) underwent lung biopsies. LCH was diagnosed with extrapulmonary tissue biopsies, even for some cases with diffuse pulmonary infiltrations. However, for these cases, the clinical characters and extrapulmonary pathological manifestations were sufficient for the diagnosis of LCH, and to avoid excessive damage, lung biopsies were not performed. Third, peripheral blood BRAF^V600E^ mutations for LCH cases had been previously reported, and the mutation status might be associated with the disease burden and therapy response.[23](#tca13179-bib-0023){ref-type="ref"}, [24](#tca13179-bib-0024){ref-type="ref"}, [25](#tca13179-bib-0025){ref-type="ref"}, [26](#tca13179-bib-0026){ref-type="ref"} As our study was retrospective, we were unable to obtain samples from all enrolled cases, and most of them were treated when we connect with them. Peripheral blood BRAF^V600E^ mutation status will be analyzed in our future prospective studies, especially for MS‐LCH cases.

In conclusion, the BRAF^V600E^ mutation rate in patients with LCH was lower than in some reported studies. In addition, BRAF^V600E^ mutations might not correlated with age, gender, LCH classification type, or prognosis in our patients with LCH.
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